Fate Therapeutics presents updated Phase 1 data for FT819 CAR T-cell candidate in lupus nephritis at ASN Kidney Week 2026

Fate Therapeutics presented updated Phase 1 clinical data for FT819, its off-the-shelf, iPSC-derived anti-CD19 CAR T-cell product candidate, in patients with SLE with lupus nephritis at ASN Kidney Week 2026. The presentation serves as a key update on the FT819 program's progress.

Detected & updated continuously · Source: Nebula